GlobeNewswire

Mandalay Resources Corporation Announces Production and Sales Results for the First Quarter 2018

Dela

TORONTO, April 12, 2018 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX:MND) announced today its production and sales results for the first quarter of 2018.

In the first quarter of 2018, Mandalay produced a consolidated 23,172 saleable ounces of gold equivalent and sold 29,151 ounces of gold equivalent.

Mark Sander, President and Chief Executive Officer of Mandalay, commented, "Mandalay's production and sales results for the first quarter of 2018 place us firmly on track to reach our 2018 production guidance of 101,000 to 113,000 gold equivalent ounces."

Dr. Sander continued, "Björkdal produced 12,716 ounces of gold in the first quarter of 2018, about 20% higher than the comparative year-ago quarter. Also in the current quarter, Björkdal recorded the second highest sales under Mandalay ownership at 17,677 gold ounces. This occurred as inventory from the record fourth quarter 2017 production was sold. Follow-on revenue due to the high sales volume in the first quarter will strengthen our cash position."

Dr. Sander concluded, "Costerfield produced 10,456 gold equivalent ounces in the first quarter of 2018. First quarter production was comparatively lower than in the previous year quarter due to expected lower mining grades.  We are on track with respect to the capital development program, announced in November 2017, to reach the Brunswick Lode, which we expect will open up additional production fronts and extend mine life. Simultaneously, we are aggressively continuing infill and extensional drilling in the recently announced Youle vein target, for which we released some very encouraging high-grade intercepts earlier this April (see Mandalay April 3, 2018 press release)."

Saleable production for the three months ended March 31, 2018:

  • The Company produced a total of 19,303 ounces of gold and 605 tonnes of antimony, representing a total of 23,172 ounces of gold equivalent in the first quarter of 2018, versus 21,370 ounces of gold, 741 tonnes of antimony and 435,076 ounces of silver, representing a total of 32,481 ounces of gold equivalent in the first quarter of 2017 when Cerro Bayo was operating. 
     
  • The Björkdal mine (Sweden) produced 12,716 ounces of gold in the first quarter of 2018, as compared to 10,648 ounces of gold in the first quarter of 2017.
     
  • The Costerfield mine (Australia) produced 6,587 ounces of gold and 605 tonnes of antimony in the first quarter of 2018, versus 7,987 ounces of gold and 741 tonnes of antimony in the first quarter of 2017. 
     
  • The Cerro Bayo mine (Chile) produced no metal in the first quarter of 2018 because it remains on care and maintenance due to the inundation event of June 2017. By comparison, in the previous year first quarter, it produced 435,076 ounces of silver and 2,735 ounces of gold.

Table 1 - Saleable Production for the First Quarter 2018 and 2017, and Fourth Quarter 2017

Metal Source Three months
ended 

31 March
2018
Three months
ended 

31 March
2017
Three months
ended

31 December
2017
Gold (oz) Björkdal 12,716 10,648 22,035
  Costerfield 6,587 7,987 7,222
  Cerro Bayo - 2,735 -
  Total 19,303 21,370 29,257
Antimony (t) Costerfield 605 741 805
Silver (oz) Cerro Bayo - 435,076 -
Average quarterly prices:        
Gold US$/oz   1,329 1,217 1,275
Antimony US$/t   8,499 8,058 8,137
Silver US$/oz   16.77 17.36 16.71
Au Eq. (oz)1 Björkdal 12,716   10,648 22,035
  Costerfield 10,456 12,891  12,360
  Cerro Bayo - 8,942 -
  Total 23,172 32,481 34,395

1  Quarterly gold equivalent ounces ("Au Eq. oz") produced is calculated by multiplying the saleable quantities of gold ("Au"), silver ("Ag"), and antimony ("Sb") in the period by the respective average market prices of the commodities in the period, adding the three amounts to get a "total contained value based on market price", and then dividing that total contained value by the average market price of Au in the period.  Average Au price in the period is calculated as the average of the daily LME PM fixes in the period, with price on weekend days and holidays taken of the last business day; average Sb price in the period is calculated as the average of the daily average of the high and low Rotterdam warehouse prices for all days in the period, with price on weekend days and holidays taken from the last business day; average Ag price in the period is calculated as the average of the daily London Broker's silver spot price for all days in the period, with price on weekend days and holidays taken from the last business day. The source for all prices is www.metalbulletin.com.

Sales for the three months ended March 31, 2018:

  • The Company sold 24,808 ounces of gold and 679 tonnes of antimony, representing a total of 29,151 ounces of gold equivalent in the first quarter of 2018, versus 23,668 ounces of gold, 708 tonnes of antimony, and 451,777 ounces of silver, representing a total of 34,801 ounces of gold equivalent in the first quarter of 2017 when Cerro Bayo was operating.
     
  • Björkdal sold 17,677 ounces of gold in the first quarter of 2018, versus 13,121 ounces of gold in the first quarter of 2017.
     
  • Costerfield sold 7,131 ounces of gold and 679 tonnes of antimony in the first quarter of 2018, versus 7,547 ounces of gold and 708 tonnes of antimony in the first quarter of 2017.
     
  • Cerro Bayo sold nothing in the first quarter of 2018, as production has been suspended since June 2017.

Table 2 - Sales for the First Quarter 2018 and 2017, and Fourth Quarter 2017

Metal Source Three months
ended 

31 March
2018
Three months
ended 

31 March
2017
Three months
ended

31 December
2017
Gold (oz) Björkdal 17,677 13,121 18,565
  Costerfield 7,131 7,547 6,337
  Cerro Bayo - 3,000 142
  Total 24,808 23,668 25,044
Antimony (t) Costerfield 679 708 668
Silver (oz) Cerro Bayo - 451,777 18,334
Average quarterly prices:        
Gold US$/oz   1,329 1,217 1,275
Antimony US$/t   8,499 8,058 8,137
Silver US$/oz   16.77 17.36 16.71
Au Eq. (oz)1 Björkdal 17,677 13,121 18,565
  Costerfield 11,474 12,235  10,599
  Cerro Bayo - 9,445 383
  Total 29,151 34,801 29,547

1 Quarterly Au Eq. oz sold is calculated by multiplying the saleable quantities of Au, Ag, and Sb in the period by the respective average market prices of the commodities in the period, adding the three amounts to get a "total contained value based on market price", and then dividing that total contained value by the average market price of Au for the period. The source for all prices is www.metalbulletin.com with price on weekend days and holidays taken of the last business day.

For Further Information:

Mark Sander
President and Chief Executive Officer

Greg DiTomaso
Director of Investor Relations

Contact: 
647.260.1566

About Mandalay Resources Corporation:

Mandalay Resources is a Canadian-based natural resource company with producing assets in Australia and Sweden, and care and maintenance and development projects in Chile. The Company is focused on executing a roll-up strategy, creating critical mass by aggregating advanced or in production gold, copper, silver and antimony projects in Australia, the Americas and Europe to generate near-term cash flow and shareholder value.

Forward-Looking Statements:

This news release contains "forward-looking statements" within the meaning of applicable securities laws, including statements regarding the Company's production of gold, silver and antimony for the 2018 fiscal year. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, changes in commodity prices and general market and economic conditions. The factors identified above are not intended to represent a complete list of the factors that could affect Mandalay. A description of additional risks that could result in actual results and developments differing from those contemplated by forward-looking statements in this news release can be found under the heading "Risk Factors" in Mandalay's annual information form dated March 29, 2018, a copy of which is available under Mandalay's profile at www.sedar.com. In addition, there can be no assurance that any inferred resources that are discovered as a result of additional drilling will ever be upgraded to proven or probable reserves. Although Mandalay has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Mandalay Resources Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum